A new study finds that patients taking GLP-1 receptor agonists for diabetes or weight loss experience fewer serious complications after surgery, including lower rates of heart-related issues and infections. The research analyzed data from over two million adults who underwent various surgical procedures, comparing outcomes between those using the medications and those who did not. Results indicate a protective association that persisted across different types of operations and patient demographics.
GLP-1 medications, such as semaglutide and liraglutide, work by mimicking a hormone that regulates blood sugar and appetite. Beyond their primary uses, these drugs have shown anti-inflammatory and cardiovascular benefits in prior research. In this study, researchers observed that patients on GLP-1 therapy had significantly reduced incidences of postoperative myocardial infarction, stroke, and severe infections like sepsis. The findings suggest the medications may stabilize metabolic and inflammatory responses during the surgical stress period, though the exact mechanisms remain under investigation.
The study relied on large-scale electronic health record data, which allows for broad population insights but cannot establish direct causation. Researchers adjusted for confounding factors such as age, comorbidities, and surgical type, yet residual biases cannot be fully ruled out. Experts caution that while the associations are compelling, randomized trials are needed to confirm whether GLP-1 drugs actively prevent complications or if healthier patients are simply more likely to be prescribed them. Ongoing trials are examining perioperative use of these agents in high-risk surgical candidates.
Current clinical guidelines vary, with some advising discontinuation due to risks like delayed gastric emptying and aspiration under anesthesia. However, this study’s findings may prompt a reevaluation of those recommendations, particularly for patients with cardiovascular or metabolic risk. Doctors emphasize that any decision to continue or pause GLP-1 therapy should be individualized, weighing surgical risks against the potential benefits of sustained glycemic and inflammatory control. Multidisciplinary consultation is encouraged to optimize perioperative management.
What types of surgeries were included in the study? The analysis covered a broad range of procedures, including orthopedic, cardiovascular, gastrointestinal, and oncological surgeries, across diverse hospital settings.
Do GLP-1 medications eliminate surgical risks entirely? No, the study shows a reduction in relative risk, not elimination; patients on these drugs still experienced complications, albeit at lower rates than non-users.
Are there specific GLP-1 drugs that performed better than others? The study did not differentiate significantly between individual agents, as most patients were on either semaglutide or liraglutide, with similar trends observed across the class.